T3 hormone in hypothyroid patients

Effect of Liothyronine (T3) supplementation in Symptomatic Patients of Hypothyroidism Having Normal TSH with Levothyroxine: A Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/110444

Enrollment

Registered

2026-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

Intervention1: LT3(Liotyronine) + LT4 (Levothyroxine): The existing dose of LT4 will be reduced and LT3 added in a ratio of 3 : 1. Dose will be titrated at 6 weeks and at 3 months to maintain TSH in n

Eligibility

Inclusion criteria

Inclusion criteria: Patients with hypothyroidism due to Hashimotos thyroiditis on a stable dose of LT4 for 6 months with normal TSH

Exclusion criteria

Exclusion criteria: Poor compliance to levothyroxine,osteoporosis due to any etiology, cardiac arrhyhthmias, Coronary artery disease, heart failure, unable to understand and respond to standardised questionnairres, having other comorbidities or health conditions that can affect quality of life

Design outcomes

Primary

Measure	Time frame
Improvement in quality of lifeTimepoint: 0 (baseline) and 6 months	—

Secondary

Measure	Time frame
Body compositionTimepoint: 0 (baseline) and 6 months;Metabolic parametersTimepoint: 0 (baseline) and 6 months;Bone mineral density (BMD)Timepoint: 0 (baseline) and 6 months	—

Countries

India

Contacts

Public ContactSoumik Goswami

NRS Medical College

dr.soumikgoswami@gmail.com9903950841

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026